CN104755086A - 四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途 - Google Patents

四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途 Download PDF

Info

Publication number
CN104755086A
CN104755086A CN201380055135.1A CN201380055135A CN104755086A CN 104755086 A CN104755086 A CN 104755086A CN 201380055135 A CN201380055135 A CN 201380055135A CN 104755086 A CN104755086 A CN 104755086A
Authority
CN
China
Prior art keywords
amino
pyrazolo
compound
pyrimidine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380055135.1A
Other languages
English (en)
Chinese (zh)
Inventor
V·克莱林
J·盖尔
N·塔米米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN104755086A publication Critical patent/CN104755086A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380055135.1A 2012-10-23 2013-10-09 四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途 Pending CN104755086A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717429P 2012-10-23 2012-10-23
US61/717,429 2012-10-23
PCT/IB2013/059239 WO2014064566A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Publications (1)

Publication Number Publication Date
CN104755086A true CN104755086A (zh) 2015-07-01

Family

ID=49765599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055135.1A Pending CN104755086A (zh) 2012-10-23 2013-10-09 四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途

Country Status (15)

Country Link
US (2) US20150274735A1 (https=)
EP (1) EP2911672A1 (https=)
JP (1) JP2015534977A (https=)
KR (1) KR20150056853A (https=)
CN (1) CN104755086A (https=)
AU (1) AU2013336293B2 (https=)
BR (1) BR112015008380A2 (https=)
CA (1) CA2888160A1 (https=)
HK (1) HK1211850A1 (https=)
IL (1) IL238374A0 (https=)
IN (1) IN2015DN03190A (https=)
MX (1) MX2015005004A (https=)
RU (1) RU2015115005A (https=)
SG (1) SG11201502286XA (https=)
WO (1) WO2014064566A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939328B1 (ko) * 2012-12-21 2019-01-16 주식회사 엘지화학 신규한 구조를 가지는 중공사막 및 그 제조 방법
EP3925957A4 (en) 2019-02-15 2022-11-02 Tohoku University 1,3-DIOXOLANE DERIVATIVE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016262A1 (en) * 2004-08-10 2006-02-16 Pfizer Limited Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
WO2007054778A1 (en) * 2005-11-10 2007-05-18 Pfizer Products Inc. Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors
CN101175758A (zh) * 2005-05-12 2008-05-07 辉瑞有限公司 N－[1－(2－乙氧基乙基)－5－(N－乙基－N－甲基氨基)－7－(4－甲基吡啶－2－基－氨基)－1H－吡唑并[4,3－d]嘧啶－3－羰基]甲磺酰胺的无水结晶形式

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2608018C (en) * 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016262A1 (en) * 2004-08-10 2006-02-16 Pfizer Limited Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
CN101175758A (zh) * 2005-05-12 2008-05-07 辉瑞有限公司 N－[1－(2－乙氧基乙基)－5－(N－乙基－N－甲基氨基)－7－(4－甲基吡啶－2－基－氨基)－1H－吡唑并[4,3－d]嘧啶－3－羰基]甲磺酰胺的无水结晶形式
WO2007054778A1 (en) * 2005-11-10 2007-05-18 Pfizer Products Inc. Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors

Also Published As

Publication number Publication date
CA2888160A1 (en) 2014-05-01
WO2014064566A1 (en) 2014-05-01
US20160136170A1 (en) 2016-05-19
AU2013336293A1 (en) 2015-04-09
JP2015534977A (ja) 2015-12-07
KR20150056853A (ko) 2015-05-27
MX2015005004A (es) 2015-07-17
SG11201502286XA (en) 2015-05-28
HK1211850A1 (en) 2016-06-03
BR112015008380A2 (pt) 2017-07-04
IN2015DN03190A (https=) 2015-10-02
EP2911672A1 (en) 2015-09-02
AU2013336293B2 (en) 2016-05-12
US20150274735A1 (en) 2015-10-01
RU2015115005A (ru) 2016-12-20
IL238374A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
CN117105939B (zh) 稠合双环sGC刺激剂
EP3194395B1 (en) Sgc stimulators
CA2534432A1 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
WO2022174269A1 (en) Irak4 degraders and uses thereof
EP2063875A2 (en) Combination pharmaceutical compositions
CN110152000A (zh) 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物
JP2016540017A (ja) ｓＧＣ刺激物質
CN101237838A (zh) 治疗免疫炎性疾病的联合疗法
TW201011029A (en) Organic compounds for wound healing
Sun et al. Cyclopropyl scaffold: A generalist for marketed drugs
KR20090094090A (ko) 치료를 위한 방법 및 조성물
JP2007169278A (ja) Ｌｕｔｓ処置用の医薬組合せ
TW202034921A (zh) 癌症療法
CN104755086A (zh) 四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途
EP2007352B1 (en) Treatment of psychiatric patients with sleep disturbances and/or excessive daytime sleepiness with paliperidone
WO2010097501A2 (en) A combination treatment
JP2006517557A (ja) 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用
US20100249103A1 (en) combination treatment
CN100502862C (zh) 减少与来氟米特治疗相关毒性的方法和组合物
WO2015016694A1 (es) Composición sólida estable de inmunosupresores
HK40001613B (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
IE20080349A1 (en) A pharmacuetical composition
CN101460143A (zh) 用帕潘立酮治疗患有睡眠障碍和/或白天过度嗜睡的精神病患者的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211850

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211850

Country of ref document: HK